Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans

Open access

Published version of a preprint

Abstract

BACKGROUND: CTLA4 blocking monoclonal antibodies provide durable clinical benefit in a subset of patients with advanced melanoma mediated by intratumoral lymphocytic infiltrates. A key question is defining whether the intratumoral infiltration (ITI) is a differentiating factor between patients with and without tumor responses. METHODS: Paired baseline and postdosing tumor biopsy specimens were prospectively collected from 19 patients with metastatic melanoma, including 3 patients with an objective tumor response, receiving the anti-CTLA4 antibody tremelimumab within a clinical trial with primary endpoint of quantitating CD8(+) cytotoxic T-lymphocyte (CTL) infiltration in tumors. Samples were analyzed for cell density by automated imaging capture and further characterized for functional lymphocyte properties by assessing the cell activation markers HLA-DR and CD45RO, the cell proliferation marker Ki67, and the regulatory T-cell marker FOXP3. RESULTS: There was a highly significant increase in ITI by CD8(+) cells in biopsy samples taken after tremelimumab treatment. This included increases between 1-fold and 100-fold changes in 14 of 18 evaluable cases regardless of clinical tumor response or progression. There was no difference between the absolute number, location, or cell density of infiltrating cells between clinical responders and patients with nonresponding lesions that showed acquired intratumoral infiltrates. There were similar levels of expression of T-cell activation markers (CD45RO, HLA-DR) in both groups and no difference in markers for cell replication (Ki67) or the suppressor cell marker FOXP3. CONCLUSION: CTLA4 blockade induces frequent increases in ITI by T cells despite which only a minority of patients have objective tumor responses.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1158/1078-0432.ccr-11-0407

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 162

Metadata

Authors
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., Glaspy, J. A., Cochran, A. J., & Ribas, A.
Affiliations
  • University of California, Los Angeles (US)
  • Authors' Affiliations: Departments of 1Pathology and Laboratory Medicine, 2Medicine, Division of Hematology/Oncology, and 3Surgery, Division of Surgical Oncology, and 4Jonsson Comprehensive Cancer Center, University of California, Los Angeles (UCLA), Los Angeles, California; and 5Pfizer Global Research and Development, New London, Connecticut
Corresponding author
Ribas, Antoni
Venue
Clinical Cancer Research
Published
2011-06-15
Volume
17
Issue
12
Pages
4101-4109
ISSN
  • 1078-0432 (ISSN-L)
  • 1557-3265
OpenAlex
W2166626276
Cited by
157
References
40
Citations by year
2026: 4 · 2025: 2 · 2024: 8 · 2023: 9 · 2022: 15 · 2021: 7 · 2020: 6 · 2019: 15 · 2018: 11 · 2017: 16 · 2016: 16 · 2015: 13 · 2014: 8 · 2013: 12 · 2012: 11
FWCI
5.35
Type
journal article
Language
en
Open access
Locations
  • Clinical Cancer Research (publishedVersion)
  • PubMed (publishedVersion)
  • Europe PMC (PubMed Central) (acceptedVersion)
  • PubMed Central (acceptedVersion)
Funders
  • Pfizer
  • California Institute of Technology
  • National Institutes of Health (5u54ca119347-03)
  • National Cancer Institute (K23CA093376, U54-CA119347, 2U54 CA119347)
  • Jonsson Cancer Center Foundation
Topics
  • Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
  • Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
  • Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords
CTLA-4 blockade, tremelimumab, metastatic melanoma, intratumoral lymphocyte infiltration, CD8+ cytotoxic T lymphocytes, antitumor immunity, T cell activation markers, HLA-DR, CD45RO, Foxp3+ regulatory T cells, Ki-67 cell proliferation, anti-CTLA-4 antibody, tumor response prediction
MeSH terms
Adult, Aged, Aged, 80 and over, Antibodies, Monoclonal, Biopsy, Female, Humans, Lymphocyte Activation, Male, Melanoma, Middle Aged, Neoplasm Staging, Phenotype, T-Lymphocytes, Antigens, CD, Lymphocytes, Tumor-Infiltrating, Treatment Outcome, Antibodies, Blocking, CTLA-4 Antigen, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. https://app.cochat.ai/papers/10.1158/1078-0432.ccr-11-0407
The paper
Huang, R. R., Jalil, J., Economou, J. S., Chmielowski, B., Koya, R. C., Mok, S., Sazegar, H., Seja, E., Villanueva, A., Gomez-Navarro, J., Glaspy, J. A., Cochran, A. J., & Ribas, A. (2011). CTLA4 Blockade Induces Frequent Tumor Infiltration by Activated Lymphocytes Regardless of Clinical Responses in Humans. Clinical Cancer Research. https://doi.org/10.1158/1078-0432.ccr-11-0407

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.